Asset
Casdozokitug
Coherus Oncology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05359861 | phase2 | completed | 2022-04-12 | 2025-06-30 | Coherus Oncology, Inc. | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma |
FDA applications (0)
This company has no applications containing this asset.